Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Leukemia 1Hodgkin Disease 1Hematologic Diseases 1Ganglioneuroblastoma 1

Interventions

Cytarabine 48Cyclophosphamide 41Etoposide 34fludarabine phosphate 26Filgrastim 26Peripheral Blood Stem Cell Transplantation 25Radiotherapy 24Daunorubicin 24Vincristine 20Methotrexate 20Busulfan 18Mitoxantrone 15Idarubicin 15Doxorubicin 13Dexamethasone 13Rituximab 12Asparaginase 12Prednisone 11Mercaptopurine 11Cyclosporine 11Thioguanine 9Leucovorin 9Ifosfamide 9Antilymphocyte Serum 9laromustine 8Prednisolone 8fludarabine 7Methylprednisolone 7Interferon-alpha 7aldesleukin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia × Leukapheresis × Clear all
NCT03226704 2026-05-20

Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

National Institutes of Health Clinical Center (CC)

Enrolling by invitation
120 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡